Miniatura

Fitxers

662772.pdf (2.56 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2013-11-10

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/126017

A prognostic DNA methylation signature for stage I non-small-cell lung cancer

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1200/JCO.2012.48.5516

Resum

Purpose Non-small-cell lung cancer (NSCLC) is a tumor in which only small improvements in clinical outcome have been achieved. The issue is critical for stage I patients for whom there are no available biomarkers that indicate which high-risk patients should receive adjuvant chemotherapy. We aimed to find DNA methylation markers that could be helpful in this regard. Patients and Methods A DNA methylation microarray that analyzes 450,000 CpG sites was used to study tumoral DNA obtained from 444 patients with NSCLC that included 237 stage I tumors. The prognostic DNA methylation markers were validated by a single-methylation pyrosequencing assay in an independent cohort of 143 patients with stage I NSCLC. Results Unsupervised clustering of the 10,000 most variable DNA methylation sites in the discovery cohort identified patients with high-risk stage I NSCLC who had shorter relapse-free survival (RFS; hazard ratio [HR], 2.35; 95% CI, 1.29 to 4.28; P = .004). The study in the validation cohort of the significant methylated sites from the discovery cohort found that hypermethylation of five genes was significantly associated with shorter RFS in stage I NSCLC: HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9. A signature based on the number of hypermethylated events distinguished patients with high-and low-risk stage I NSCLC (HR, 3.24; 95% CI, 1.61 to 6.54; P = .001). Conclusion The DNA methylation signature of NSCLC affects the outcome of stage I patients, and it can be practically determined by user-friendly polymerase chain reaction assays. The analysis of the best DNA methylation biomarkers improved prognostic accuracy beyond standard staging. (C) 2013 by American Society of Clinical Oncology.

Matèries

Càncer de pulmó, Metilació, ADN

Matèries (anglès)

Lung cancer, Methylation, DNA

Citació

Col·leccions

Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SANDOVAL, Juan, MÉNDEZ GONZÁLEZ, Jesús, NADAL, Ernest, CHEN, Guoan, CARMONA, F. javier, SAYOLS, Sergi, MORAN, Sebastian, HEYN, Holger, VIZOSO, Miguel, GÓMEZ, Antonio, SÁNCHEZ CÉSPEDES, Montserrat, ASSENOV, Yassen, MÜLLER, Fabian, BOCK, Christoph, TARON, Miquel, MORA, Josefina, MUSCARELLA, Lucia a., LILOGLOU, Triantafillos, DAVIES, Michael p. a., POLLÁN, Marina, PAJARES, María josé, TORRE, Wenceslao, MONTUENGA, Luis m., BRAMBILLA, Elisabeth, FIELD, John k., ROZ, Luca, LO IACONO, Marco, SCAGLIOTTI, Giorgio v., ROSELL COSTA, R., BEER, David g., ESTELLER, Manel. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. _Journal of Clinical Oncology_. 2013. Vol. 31, núm. 32, pàgs. 4140-4147. [consulta: 22 de gener de 2026]. ISSN: 0732-183X. [Disponible a: https://hdl.handle.net/2445/126017]

Exportar metadades

JSON - METS

Compartir registre